Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer

ONCOLOGY

Volumn 13, Issue 7 SUPPL., 1999, Pages 82-85

  Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; UFT;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG TOLERABILITY; ERYTHEMA; HEARING LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LETHARGY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HUMANS; LEUCOVORIN; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0032806962     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Sullivan RD, Young CW, Miller E, et al: The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-5-deoxyuridine). Cancer Chemother Rep 8:77-81, 1960.
2. Cameron DA, Gabra H, Leonard RCF: Con tinuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70:120-124, 1994.
3. Huan S, Pazdur S, Singhakowinta A, et al: Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast cancer. Cancer 63:419-422, 1989.
4. Regazzoni S, Pesce G, Marini G, et al: Low- dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7:807-813, 1996.
5. Jones AL, Smith TE, O'Brien MER, et al: Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer. J Clin Oncol 12:1259-1265, 1994.
6. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995.
7. Calvert AH, Newell DR, Gumbrell LA, et al: Early clinical studies with cis-dianimine-1 1- cycloburant dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982.
8. Henderson K, Harris JR, Kinne DW, et al: Cancer of the breast, in DeVita VT Jr, Hell man S. Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 3rd ed, pp 1197-1268. Philadelphia, JB Lippincott Co, 1989.
9. Bennett JM, Muss HB, Doroshow DH, et al: A randomized, multicenter trial comparing mitoxantrone, cyclophosphamidc, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast cancer. J Clin Oncol 6:1611-1620, 1988.
10. Eisen T, Smith TE, Johnston S, et al: A randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 16:1350-1357, 1998.
11. Puig-la Calle Jr J, Lopez Sanchez S, Piedrafita Serra E, et al: Totally implanted device for long-term iv chemotherapy: Experiences in 123 adult patients with solid neoplasms. J Surg Oncol 62:273-278, 1996.
12. Fujii S, Ikenaka K, Fukushima M, et al: Effect of uracil and its derivatives on antitumour activity of 5-fluorouracil 1-(2-tetrahydrofuryl) 5-fluorouracil. Kagaku Ryoho 69:763-772, 1978.